Business

Mass. Movers

Insulet narrows loss in fourth quarter

An earlier version of Insulet’s OmniPod insulin pump.

An earlier version of Insulet’s OmniPod insulin pump.

Advertisement

Bedford’s Insulet Corp. said fourth-quarter 2013 revenue rose 19 percent to $68.5 million, compared to $57.8 million in the same period in 2012. Insulet said the revenue bump was a result of continued strong patient adoption of the OmniPod insulin pump in the United States and international markets. The company said its net loss was $2.5 million, or 4 cents per share, compared to a loss of $10.2 million, or 21 cents, in 2012. The results, however, beats analysts’ estimated loss of 9 cents.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.